Navigation Links
2nd Day of Testimony: Mainor Eglet Attorney Continues Questioning Teva Pharmaceuticals Vice President
Date:8/24/2011

LAS VEGAS, Aug. 24, 2011 /PRNewswire/ -- "Production of Propofol was stopped after the Chanin trial in 2010 due to public outcry," said Robert Eglet attorney for the plaintiffs. In a stunning turn in the Anne Arnold Hepatitis C trial in Clark County, Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admits under examination by Eglet that Teva turned the lights out in their Propofol plant 21 days after last years verdict. 

(Photo:  http://photos.prnewswire.com/prnh/20110824/LA56965)

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

This is the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected. In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs. 

Craig Lea takes the stand for day 3 of
'/>"/>

SOURCE Mainor Eglet
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
2. Mainor Eglet Attorney, Robert Eglet, Calls Teva Pharmaceuticals Vice President Craig Lea to the Stand in Hepatitis C Trial
3. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
4. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
5. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
6. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
7. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
8. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
9. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
10. CVS/pharmacy Announces Agreements With U.S. Drug Enforcement Administration and U.S. Attorneys Offices
11. Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys Fees and Reimbursement of Litigation Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , HARBIN, China, Nov. 17 /PRNewswire-Asia-FirstCall/ ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical company in ... the third quarter,of 2009. , , Third Quarter ... to $43.2 million, -- Gross profit increased 44.8% ...
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
Cached Medicine Technology:China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 10The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... more than one out of three survivors of ... in The Lancet Respiratory Medicine , and ... rather than mentally. , It is one of ... and functional outcomes of critical care survivors, according ... of Medicine, and it highlights a significant public ...
(Date:4/24/2014)... team of researchers was the first in the world ... a tumour of the jaw. , Ameloblastoma is an ... treatment. Ameloblastoma is most often found in the posterior ... often resulting in tissue deficiencies in the jaws as ... therapy could reduce the need for surgery and the ...
(Date:4/24/2014)... University researcher has found a relationship between motor skill ... spectrum disorder in very young children. , The ... a direct relationship between motor skills and autism severity, ... should be included in treatment plans for young children ... OSU,s College of Public Health and Human Sciences. ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
... Goodman Steps Down; John Walker, Board Chair, Named Executive ... ... Renovis,Inc. (Nasdaq: RNVS ), a biopharmaceutical company focused on the ... and inflammatory diseases, today announced that Corey Goodman,Ph.D., will step down today ...
... approve gastric band for adolescents by 2009, WALTHAM, ... gastric band market, currently valued at over $190,million, will ... approval,of the LAP-BAND device for adolescents aged 14 to ... of the most rapidly growing,segments of the obese population, ...
... Concentra was recently announced,as a silver ... Awards, sponsored by,ComPsych Corporation. Concentra was selected ... participation rates,and achieved results. Concentra, a ... for its commitment to better health and ...
... Oct. 1 Mylan Laboratories Inc.,(NYSE: MYL ) ... Vice,President and Treasurer, effective October 22, 2007. Mr. Byala ... with responsibility for,treasury planning in both New York and ... in various treasury positions of increasing responsibility.,Prior to Pfizer, ...
... Inc., a leader,in healthcare payment and cost management ... Inc. for $54 million, consisting of $44,million in ... common,stock. The acquisition will expand Viant,s PPO network ... existing lines of services to the,nation,s leading health ...
... LeMaitre Vascular,Inc., (Nasdaq: LMAT ), a provider ... has reached an agreement to launch a,direct sales force ... sells its products in Italy through an,exclusive distribution agreement ... to terminate Serom,s exclusive rights on,January 25, 2008 in ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:The Skinny on Teen Surgery 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2Health News:Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer 2Health News:Viant Acquires Texas True Choice 2Health News:LeMaitre Vascular to Start Italian Sales Force 2Health News:LeMaitre Vascular to Start Italian Sales Force 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: